Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- And NK-cell lymphoproliferative diseases

Clinical Cancer Research

Volumn 20, Issue 19, 2014, Pages 5075-5084

  Kanazawa, Tetsuhiro ^a   Hiramatsu, Yutaka ^a   Iwata, Seiko ^a   Siddiquey, Mohammed ^a   Sato, Yoshitaka ^a   Suzuki, Michio ^a   Ito, Yoshinori ^a   Goshima, Fumi ^a   Murata, Takayuki ^a   Kimura, Hiroshi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; MOGAMULIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CELL EXPANSION; CLINICAL ARTICLE; CLONAL CELL LINE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EPSTEIN BARR VIRUS INFECTION; EX VIVO STUDY; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROA VACCINIFORME; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR XENOGRAFT; VIRUS CELL INTERACTION; VOLUNTEER; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISORDERS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOPROLIFERATIVE DISORDERS; RECEPTORS, CCR4; T-LYMPHOCYTES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908276807     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0580     Document Type: Article

References (49)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-92.
2. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186-94.
3. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006;107:862-9.
4. Longnecker RM, Kieff E, Cohen JI. Epstein-Barr viru. In:Knipe DM, Howley PM, editors. Fields Virology. 6 ed. Philadelphia: Wolters kluwer/Lippincott Williams & Wilkins; 2013. p. 1898-959.
5. Song SY, Kim WS, Ko YH, Kim K, Lee MH, Park K. Aggressive natural killer cell leukemia: clinical features and treatment outcome. Haematologica 2002;87:1343-5.
6. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In:Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: WHO Press; 2008. p. 285-8.
7. Kawa K, Okamura T, Yagi K, Takeuchi M, Nakayama M, Inoue M. Mosquito allergy and Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease. Blood 2001;98:3173-4.
8. Ohshima K, Kimura H, Yoshino T, Kim CW, Ko YH, Lee SS, et al. Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD. Pathol Int 2008;58:209-17.
9. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 2009;20:1472-82.
10. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, Kojima S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012;119:673-86.
11. Ko Y-H, Kim H-J, Oh Y-H, Park G, Lee S-S, Huh J, et al. EBV-associated T and NK cell lymphoproliferative disorders: Consensus report of the 4th Asian Hematopathology Workshop. J Hematopathol 2013;5:319-24.
12. Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV+ T-cell lymphoma of childhood. In:Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: WHO Press; 2008. p. 278-80.
13. Kimura H, Miyake K, Yamauchi Y, Nishiyama K, Iwata S, Iwatsuki K, et al. Identification of Epstein-Barr virus (EBV)-infected lymphocyte subtypes by flow cytometric in situ hybridization in EBV-associated lymphoproliferative diseases. J Infect Dis 2009;200:1078-87.
14. Tanaka C, Hasegawa M, Fujimoto M, Iwatsuki K, Yamamoto T, Yamada K, et al. Phenotypic analysis in a case of hydroa vacciniforme-like eruptions associated with chronic active Epstein-Barr virus disease of gammadelta T cells. Br J Dermatol 2012;166:216-8.
15. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42.
16. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009;114:4002-8.
17. Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010;16:1520-31.
18. Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 2004;10:7529-39.
19. Yano H, Ishida T, Imada K, Sakai T, Ishii T, Inagaki A, et al. Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. Br J Haematol 2008;140:586-9.
20. Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother 2009;58:1195-206.
21. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol 2009;183:4782-91.
22. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010;28:1591-8.
23. Ohshima K, Jaffe ES, Kikuchi M. Adult T-cell leukemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4 ed. Lyon: WHO Press; 2008. p. 281-4.
24. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003;9:3625-34.
25. Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002;99:1505-11.
26. Wakugawa M, Nakamura K, Kakinuma T, Onai N, Matsushima K, Tamaki K. CC chemokine receptor 4 expression on peripheral blood CD4+ T cells reflects disease activity of atopic dermatitis. J Invest Dermatol 2001;117:188-96.
27. Maghazachi AA. G protein-coupled receptors in natural killer cells. J Leukoc Biol 2003;74:16-24.
28. Brandes M, Willimann K, Lang AB, Nam KH, Jin C, Brenner MB, et al. Flexible migration program regulates gamma delta T-cell involvement in humoral immunity. Blood 2003;102:3693-701.
29. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001;78:57-110.
30. Inngjerdingen M, Damaj B, Maghazachi AA. Expression and regulation of chemokine receptors in human natural killer cells. Blood 2001;97:367-75.
31. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008;9:970-80.
32. Zhang Y, Nagata H, Ikeuchi T, Mukai H, Oyoshi MK, Demachi A, et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 2003;121:805-14.
33. Kaplan J, Tilton J, Peterson WD Jr. Identification of T cell lymphoma tumor antigens on human T cell lines. Am J Hematol 1976;1:219-23.
34. Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol 1999;115:385-92.
35. Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000;14:922-30.
36. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996;24:406-15.
37. Murata T, Iwata S, Siddiquey MN, Kanazawa T, Goshima F, Kawashima D, et al. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. PLoS ONE 2013;8:e63566.
38. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post transplant lymphoproliferative disorders. In:Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008. p. 343-9.
39. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-31.
40. Kimura H, Hoshino Y, Kanegane H, Tsuge I, Okamura T, Kawa K, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001;98:280-6.
41. Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maeda A, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 2005;80:64-9.
42. Iwata S, Yano S, Ito Y, Ushijima Y, Gotoh K, Kawada JI, et al. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of epstein-barr virus infection. Int J Cancer 2011;129:2263-73.
43. Kawabe S, Ito Y, Gotoh K, Kojima S, Matsumoto K, Kinoshita T, et al. Application of flow cytometric in situ hybridization assay to Epstein-Barr Virus (EBV)-associated T/NK lymphoproliferative diseases. Cancer Sci 2012;103:1481-8.
44. Kawa K. Epstein-Barr virus-associated diseases in humans. Int J Hematol 2000;71:108-17.
45. Iwatsuki K, Xu Z, Takata M, Iguchi M, Ohtsuka M, Akiba H, et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 1999;140:715-21.
46. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776-80.
47. Nakayama T, Hieshima K, Arao T, Jin Z, Nagakubo D, Shirakawa AK, et al. Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene 2008;27:3221-32.
48. Zheng H, Li LL, Hu DS, Deng XY, Cao Y. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol 2007;4:185-96.
49. Tobinai K, Takahashi T, Akinaga S. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep 2012;7:235-40.